- Home
- TIGR vs ETNB Comparison
TIGR vs ETNB Comparison
Compare TIGR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIGR
- ETNB
- Stock Information
- Founded
- TIGR 2014
- ETNB 2018
- Country
- TIGR Singapore
- ETNB United States
- Employees
- TIGR N/A
- ETNB N/A
- Industry
- TIGR Investment Bankers/Brokers/Service
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- TIGR Finance
- ETNB Health Care
- Exchange
- TIGR Nasdaq
- ETNB Nasdaq
- Market Cap
- TIGR 1.4B
- ETNB 1.5B
- IPO Year
- TIGR 2019
- ETNB 2019
- Fundamental
- Price
- TIGR $9.62
- ETNB $10.15
- Analyst Decision
- TIGR Buy
- ETNB Strong Buy
- Analyst Count
- TIGR 2
- ETNB 8
- Target Price
- TIGR $8.54
- ETNB $26.43
- AVG Volume (30 Days)
- TIGR 5.5M
- ETNB 2.2M
- Earning Date
- TIGR 05-30-2025
- ETNB 08-04-2025
- Dividend Yield
- TIGR N/A
- ETNB N/A
- EPS Growth
- TIGR 93.97
- ETNB N/A
- EPS
- TIGR 0.46
- ETNB N/A
- Revenue
- TIGR $374,147,409.00
- ETNB N/A
- Revenue This Year
- TIGR $53.82
- ETNB N/A
- Revenue Next Year
- TIGR $13.18
- ETNB N/A
- P/E Ratio
- TIGR $20.50
- ETNB N/A
- Revenue Growth
- TIGR 61.42
- ETNB N/A
- 52 Week Low
- TIGR $3.36
- ETNB $4.16
- 52 Week High
- TIGR $14.48
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- TIGR 67.10
- ETNB 53.99
- Support Level
- TIGR $7.87
- ETNB $9.58
- Resistance Level
- TIGR $8.85
- ETNB $10.13
- Average True Range (ATR)
- TIGR 0.39
- ETNB 0.52
- MACD
- TIGR 0.14
- ETNB -0.12
- Stochastic Oscillator
- TIGR 76.71
- ETNB 43.62
About TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).